Kispeptin is a peptide that wasn't discovered that long ago
Wear loose and comfortable clothes that can easily be adjusted to expose the treatment zone if not removed
Se trata de un ensayo clnico aleatorizado (ECA) frente a placebo realizado en 230 lugares de 20 pases sobre 3.297 pacientes con diabetes tipo 2 (DM2) con una aleatorizacin 1/1, 1/1 a recibir 0,5 o 1,0 mg una vez semanal va subcutnea o placebo inyectable del mismo volumen (ciego) y un perodo de observacin de 109 (104 efectivas) semanas

2.4% placebo) 86.4% of participants lost at least 5% of body weight 69.1% lost at least 10% 50.5% lost at least 15% STEP 3 (Wadden et al., 2021, JAMA ): Combined with intensive behavioral therapy Average weight loss: 16.0% over 68 weeks Demonstrated that lifestyle support amplifies medication effects STEP 5 (Garvey et al., 2022, Nature Medicine ): Two-year duration study Average weight loss: 15.2% maintained over 104 weeks Demonstrated sustained effectiveness with continued use Retatrutide Clinical Trial Results Phase 2 Trial (Jastreboff et al., 2023, NEJM ): 338 adults with obesity (BMI 30+) or overweight (BMI 27+) with comorbidities Multiple dose groups (1 mg, 4 mg, 8 mg, 12 mg weekly) Results at the 12 mg dose: Average weight loss: 24.2% in 48 weeks 100% of participants lost at least 5% of body weight 93% lost at least 10% 83% lost at least 15% 63% lost at least 20% Weight loss trajectory had not plateaued at study end Comprehensive Comparison Table Side Effects Comparison Both medications share similar gastrointestinal side effect profiles because they both activate GLP-1 receptors

Vagal pathways for microbiome-brain-gut axis communication